600 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by American Assets Inc.

American Assets Inc. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 600 shares of the biopharmaceutical company's stock, valued at approximately $427,000. Regeneron Pharmaceuticals comprises 0.1% of American Assets Inc.'s portfolio, making the stock its 18th biggest position.

A number of other hedge funds have also bought and sold shares of REGN. Mizuho Securities USA LLC grew its position in shares of Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock valued at $62,382,000 after acquiring an additional 51,162 shares during the period. Principal Financial Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. grew its holdings in Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock valued at $10,082,000 after purchasing an additional 3,231 shares during the period. Golden State Equity Partners increased its position in Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock worth $967,000 after buying an additional 1,272 shares during the last quarter. Finally, Fagan Associates Inc. increased its position in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after buying an additional 3,832 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research note on Wednesday, February 5th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, December 17th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price objective for the company. Finally, Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $26.67 during trading hours on Tuesday, reaching $718.16. 1,095,531 shares of the stock traded hands, compared to its average volume of 619,238. The stock has a 50 day simple moving average of $696.96 and a two-hundred day simple moving average of $845.58. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market cap of $78.51 billion, a price-to-earnings ratio of 18.76, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $11.86 EPS. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.49%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.